Dr. Abdullah Al Emran

Assistant Professor (on study leave)

Dept. of Biotechnology and Genetic Engineering

  • Email : emran_geb@yahoo.com
  • Phone Number : N/A
  • Blood Group : B+ve

Research Interest: Cancer Biology, Cancer Epigenetics, Cancer Immunology, Drug resistance, Bioinformatics

Published articles (Selected ones):

Overall Summary:

Total citation: 518 H-Index: 12 (Source: Google Scholar: https://scholar.google.com.au/citations?user=MEUK4dMAAAAJ&hl=en&authuser=1)

  1. Dual targeting with EZH2 inhibitor and sting agonist to treat melanoma.Emran AA, Fisher DE. Journal of Investigative Dermatology. 2021, Accepted.
  1. Repurposing melanoma chemotherapy to activate inflammasomes in treatment of melanoma.Ahmed F, Tseng HY, Ahn A, Gunatilake D, Alavi S, Eccles M, Rizos H, Gallagher S, Tiffen J, Hersey P, EmranAA.Journal of Investigative Dermatology. 2021 Oct 22: S0022-202X(21)02384-8. doi: 10.1016/j.jid.2021.09.030. Media Release:

https://www.centenary.org.au/cen_news/new-discovery-tackles-treatment-resistant-melanoma/

  1. A novel combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma. Emran AA, Tseng H, Gunatilake D, Cook S, Ahmed F, Wang S, Hersey P, Gallagher S, Tiffen J. Journal of Investigative Dermatology, 2021 (IF:8.55, PMID:33781757).Media Release:https://www.centenary.org.au/cen_news/a-new-dual-drug-approach-to-treat-melanoma/, Local radio interview: 2, online news:5
  2. Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers. Punni-Moorthy G, Hersey P, Emran AA*, Tiffen J*. Frontiers Genetics, 2021 (IF:4.59, PMID: 34220955). *Equal senior author.
  1. DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma. Huang, J.C.; Emran, A.A.; Endaya, J.M.; McCaughan, G.W.; Gorrell, M.D.; Zhang, H.E. D. Cancers, 2021(IF:6.6, PMID:32731355).
  1. Sex bias of females in survival from cancer and infections.  Is X the answer? Emran AA, Gallagher SJ, Tiffen, Peter Hersey. British J Cancer, 2021(IF: 5.79, PMID: 33469152, Citation:1)
  1. Study of the female sex survival advantage in melanoma- a focus on X-linked epigenetic regulators and immune responses in two cohorts. Emran AA, JérémieNsengimana, Gaya Punnia-Moorthy, Ulf Schmitz, Stuart Gallagher, Julia Newton- Bishop, JessamyTiffen, Peter Hersey. Cancers, 2020(IF:6.6, PMID:32731355, Citation:5) Media Release:https://www.centenary.org.au/cen_news/gene-discovery-may-explain-female-melanoma-survival-advantage/, Local radio interviews:5, Lead story in Sydney Research e-Update,  online news:5
  1. Do Innate Killing Mechanisms Activated by Inflammasomes Have a Role in Treating Melanoma? Emran AA, Hsin-Yi Tseng, Mikaela C Coleman, JessemyTiffen, Stuart Cook, Stuart Gallagher, Carl Feng, Peter Hersey. PCMR, 2020 (IF: 4.69, PMID:32027447, Citation:4).
  2. Co-targeting BET proteins and Mcl-1 induces synergistic cell death in melanoma.Hsin-Yi Tseng, Jan Dreyer, Emran AA, DiliniGunatilake, Mehdi Pirozyan, Carleen Cullinane, Ken Dutton-Regester, Helen Rizos, Nicholas K Hayward, Grant McAuther, Peter Hersey, JessamyC Tiffen Stuart Gallagher. International Journal of Cancer, 2020 (IF:7.3, PMID: 32249419, Citation:9)
  3. EZH2 cooperates with DNA methylation to downregulate key tumour suppressors andrepresses interferon gene signatures in melanoma.JessamyTiffen, Stuart Gallagher, Fabian Filipp, DiliniGunatilake, Emran AA, Carleen Cullinane, Ken Dutton Register, Lauren Aoude, Nick Hayward,Aniruddha Chatterjee, Euan J Rodger, Michael R Eccles, Peter Hersey.Journal of Investigative Dermatology, 2020 (IF: 8.55, PMID: 32360600, Citations:10).
  1. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.Pirozyan MR, McGuire HM, Emran AA, Tseng HY, Tiffen JC, Lee JH, Carlino MS, Menzies AM, Long GV, Scolyer RA3, Fazekas de St Groth B, Hersey P. Frontiers in Immunology, 2020 (IF: 7.56, PMID: 32210968, Citations:9)
  1. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition. MadorskyRowdo FP, Barón A, Gallagher SJ, Hersey P, Emran AA, Von Euw EM, Barrio MM, Mordoh J. International Journal of Oncology, 2020 (IF: 5.65, PMID:32236593, Citations:6)
  1. Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer. Emran AA, Menon D, Heinz, Ahmed F, Duijf P, Schaider H. Epigenomics, 2019 (IF: 4.77, PMID, Citation:6)
  2. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.Emran AA, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR, Hersey P. Trends Immunol. 2019 (IF: 16.68, PMID:30853334, Citations:73)
  3. Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.Torrano J, Al Emran A, Hammerlindl H, Schaider H. Clin Epigenetics. 2019 (IF: 6.55, PMID:30850015, Citations:20)
  4. Magnolol induce cell death through PI3K/Aktsignaling mediated epigenetic modifications and boosts the effect of targeted inhibitors in mutant BRAF and NRAS melanoma cells.Emran AA, Chinna Chowdary BR, Ahmed F, Hammerlindl H, Huefner A, Haass NK, Schuehly W, Schaider H. Cancer Medicine, 2019 (IF: 4.45, PMID:30793515, Citation: 5). Cover image.
  1. Distinct histone modifications denote early stress induced drug tolerance in cancer. Emran AA, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, Herlyn M, Schaider H.Oncotarget, 2018(IF: 5.18, PMID:29492189, Citation:30). Priority research paper.
  1. Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS- Mutant Cancer. Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H.Clinical Cancer Research, 2017 (IF: 12.5, PMID:29196297, Citations: 12).
  1. Depression and quality of Life among postmenopausal women in Bangladesh: a cross-sectional study. Bashar M, Ahmed K, Uddin MS, Ahmed F, Emran AA, Chakraborty A. J Menopausal Med, 2016 (PMID: 29354617, Citation:9)
  1. Investigation of common disease regulatory network for metabolic disorders: A bioinformatics approach. T Jesmin, S Waheed, Emran AA, Network Biology, 2016 (Citation:7)
  1. A preliminary evaluation of cytotoxicity, antihyperglycemic and antinociceptive activity of Polygonum hydropiper L. ethanolic leaf.Arafat Rahman Oany, Al Ahad Siddikey, Mohammad Uzzal Hossain,Rafiad Islam and Abdullah Al Emran. Clinical Phytoscience, 2016 (Citation: 10).
  1. Assessment of Menopausal Symptoms among Early and Late Menopausal Midlife Bangladeshi Women and Their Impact on the Quality of Life. Ahmed K, Jahan P, Nadia I, Ahmed F, Abdullah-Al-Emran. J Menopausal Med, 2016 (PMID: 27152312, Citation:15)
  1. TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population.Chowdhury MK, Moniruzzaman M, Emran AA, Mostafa MG, Kuddus RH, Uddin MA.Asian Pac J Cancer Prev. 2015, (IF-2.5, PMID 25921167, Citations: 15).
  1. Score Based Risk Assessment of Lung Cancer and Its Evaluation for Bangladeshi People. Roushney Fatima Mukti, PratulDiptaSamadder, Abdullah Al Emran,Farzana Ahmed, Iqbal Bin Imran, AnyannaMalaker, Sabina Yeasmin. Asia Pacific Journal of Cancer Prevention, 2014 (IF-2.5, PMID: 25227785, Citations: 10).
  1. Design of an Epitope-based Peptide Vaccine against Spike Protein of Human Corona Virus: An in Silico Approach. Arafat Rahman Oany, Abdullah Al Emran. Drug Design, Development and Therapy, 2014(IF-3, PMID-25187696, Citations: 82).
  1. An Early Detection of Lung Cancer Risk Using Data Mining.Kawsar Ahmed, Abdullah Al Emran*, Tasnuba, RoushneyFatima,Md.Zamilur Rahman, Farzana Ahmed. Asia Pacific Journal of Cancer prevention. 2013 (IF-2.5, PMID: 23534801, Citations: 82).
  1. Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects. Sajal K Shaha, Sreedam Chandra Das, Abdullah Al Emran, Md. Aftab Uddin, SiteshBachar, Azad Chawdhury.Drug and Chemical Toxicology, 2012(IF-1.29, PMID: 22486205, Citations:4).
  1. Intelligent and effective diabetes risk prediction system using data mining, KAWSAR Ahmed, TASNUBA Jesmin, USHIN Fatima, M Moniruzzaman, Abdullah Al Emran, MZ Rahman. Orient J Comput Sci Technol, 2012 (Citations: 7)
  1. Evaluation of Brine shrimp lethality and Antimicrobial activity of Azadirachtaindica leaf extract on some drug resistance bacteria in Bangladesh. Abdullah Al Emran, Shahed, Farzana Ahmed, Sajal Kumar Saha, Sreedam Chandra Das, Sitesh Chandra Bachar. Pharmacognosy Journal,2011 (Citations: 6)
  1. Investigation of Antimicrobial Activity of Ethanolic Leaf- Fruit Extract of Terminalia arjuna against Multi-Drug Resistance (MDR) Bacteria in Bangladesh. Abdullah AlEmran, Farzana Ahmed, Md. SanuwarulKabir , Md. MahabuburRahaman , S.M Shahed. J ApplEnv. Biol. Sci (Citations: 3)

Conference proceedings and abstracts (published):

1. F Ahmed, A Al Emran, CA Tonnessen-Murray, B Gabrielli, M Stark, P Duijf, H Schaider, L Spoerri, N Haass. Distinct molecular signatures orchestrate tumor subpopulations in melanoma modelsmimickingtumor microenvironment and drug tolerance.  EXPERIMENTAL DERMATOLOGY. 30 (3), E110-E110.

  1. AbdullahAl Emran, HsinYi Tseng, Dilini Gunatilake, Stuart Cook, Jessamy Tiffen, Stuart Gallagher, Peter Hersey BET and CDK9 protein inhibitors: Novel epigenetic therapy to synergistically kill human melanoma cells..Cancer Research (IF-9.1). AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA, DOI: 10.1158/1538-7445.AM2020-LB-177.
  1. Jiali Huang, Abdullah Al Emran, Justine Endaya, Geoffrey McCaughan, Mark Gorrell, Hui Zhang.Associations between DPP9 expression, survival and gene expression signature in human hepatocellular carcinoma: Comprehensive in silico analyses.https://doi.org/10.1096/fasebj.2021.35.S1.04490, 2021.
  1. Al Emran, Abdullah, Menon, Dinoop Ravindran, Soyer, Peter, Gabrielli, Brian, Sturm, Rick, Herlyn, Meenhard and Schaider, Helmut (2016). Global histone modifications define early stress induced drug tolerance in cancer. Cancer Research (IF-9.1). American-Association-for-Cancer-Research (AACR) Special Conference on Chromatin and Epigenetics in Cancer, Atlanta Ga. Sep 24-27, 2015. Vol. 76 (2) doi:10.1158/1538-7445.CHROMEPI15-B34.
  1. Emran, A. A., Menon, D. R., Marzese, D., Hammerlindl, H., Brafford, P., Stark, M., Huang, S., Hammerlindl, S., Gupta, D., Soyer, P., Sturm, R., Hoon, D., Gabrielli, B., Herlyn, M. and Schaider, H. (2016). Epigenetic remodelling of H3K9Me3 leads to early stress induced drug tolerance in cancer. Australasian Journal of Dermatology(IF-1.3). Vol. 56  (17-17).
  1. Emran AA, D. M. Marzese , D. R. Menon , M. Stark , H. Hammerlindl , G. Zhang , P. Brafford , S. K. Huang , S. Hammerlindl , D. Gupta , G. Mills , Y. Lu , K. T. Flaherty , H. Peter Soyer , R. A. Sturm , D. S. B. Hoon , B. Gabrielli , M. Herlyn , H. Schaider. The H3 lysine 9 tri-methylation mark denotes early stress-induced drug tolerance in melanoma. Pigment Cell and Melanoma Research(IF-5.1). SMR Meeting Abstract 2016. DOI: 10.1111/pcmr.12547. Vol 30(1) (95-95).
  1. Menon, D. R., Hammerlindl, H., Emran, AA., Thakkar, D., Soyer, H. P., Herlyn, M., Krepler, C. and Schaider, H. (2016). Combination of sorafenib with aspirin synergistically target mutant NRAS melanomaAustralasian Journal of Dermatology (IF-1.3). Vol. 56 (25-26).
  1. Schaider, H., Menon, D. R., Emran, AA., Gabrielli, B., Haass, N., Somasundaram, R. and Herlyn, M. (2016). Stress induced multi-drug tolerance precedes acquired drug resistance in melanoma. Australasian Journal of Dermatology(IF-1.3).Vol. 56 (12-12).
  1. Acetylsalicylic acid governs the effect of Sorafenib inmutant NRAS melanoma. H. Hammerlindl, D. R. Menon1, S. Katrin, D. Thakkar, A. A.Emran, N. Haass, B. Gabrielli, V. Atkinson, M. Herlyn, C.Krepler, H. Schaider. Pigment Cell and Melanoma Research (IF-5.1). SMR Meeting Abstract 2016. DOI: 10.1111/pcmr.12547. Vol 30(1) (102-102).
  1. The AMPK- OGT axis prevents acquired drug resistancethrough inhibition of drug induced epigeneticremodelling in melanoma. D. R. Menon, H. Hammerlindl, J. Torrano, A. A. Emran,S.Hammerlindl, G. Zhang, R. Somasundaram, H. Peter Soyer,K. T. Flaherty, R. A. Sturm, N. Haass, B. Gabrielli, M. Herlyn,H. Schaider.Pigment Cell and Melanoma Research(IF-5.1). SMR Meeting Abstract 2016. DOI: 10.1111/pcmr.12547. Vol 30(1) (140-140).